558 related articles for article (PubMed ID: 29423715)
1. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
[TBL] [Abstract][Full Text] [Related]
2. Prediction of Fracture Risk From Early-Stage Bone Markers in Patients With Osteoporosis Treated With Once-Yearly Administered Zoledronic Acid.
Kasai H; Mori Y; Ose A; Shiraki M; Tanigawara Y
J Clin Pharmacol; 2021 May; 61(5):606-613. PubMed ID: 33135182
[TBL] [Abstract][Full Text] [Related]
3. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
Iba K; Sonoda T; Takada J; Dohke T; Yamashita T
J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
[TBL] [Abstract][Full Text] [Related]
4. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Kondo H; Okimoto N; Yoshioka T; Akahoshi S; Fuse Y; Ogawa T; Okazaki Y; Katae Y; Tsukamoto M; Yamanaka Y; Kawasaki M; Sakai A
J Bone Miner Metab; 2020 Nov; 38(6):894-902. PubMed ID: 32656645
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Efficacy of Zoledronate Acid or Denosumab After Switching from Romosozumab in Japanese Postmenopausal Patients.
Oue T; Shimizu T; Asano T; Shimodan S; Ishizu H; Arita K; Iwasaki N
Calcif Tissue Int; 2023 Jun; 112(6):683-690. PubMed ID: 37037949
[TBL] [Abstract][Full Text] [Related]
7. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
Zhou W; Liu Y; Guo X; Yang H; Xu Y; Geng D
Osteoporos Int; 2019 Aug; 30(8):1581-1589. PubMed ID: 31115592
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of discontinuing risedronate for patients with systemic lupus erythematosus: a prospective study.
Ishida T; Yoshida S; Kimura Y; Fujiki Y; Kotani T; Takeuchi T; Makino S; Arawaka S
Lupus; 2018 Sep; 27(10):1636-1643. PubMed ID: 29954283
[TBL] [Abstract][Full Text] [Related]
9. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis.
Koldkjær Sølling AS; Harsløf T; Langdahl B
Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367
[TBL] [Abstract][Full Text] [Related]
10. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
Nakatoh S
J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
[TBL] [Abstract][Full Text] [Related]
11. Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Roux C; Reid DM; Devogelaer JP; Saag K; Lau CS; Reginster JY; Papanastasiou P; Bucci-Rechtweg C; Su G; Sambrook PN
Osteoporos Int; 2012 Mar; 23(3):1083-90. PubMed ID: 21975559
[TBL] [Abstract][Full Text] [Related]
12. Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis.
Watanabe D; Kimura T; Watanabe K; Takano H; Uehara Y; Minowa T; Yamashita A; Yoshikawa S; Mizushima A
BMC Cancer; 2021 Apr; 21(1):422. PubMed ID: 33863312
[TBL] [Abstract][Full Text] [Related]
13. The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study.
Nakatoh S
J Bone Miner Metab; 2016 Mar; 34(2):216-24. PubMed ID: 26031934
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
Suzuki T; Nakamura Y; Kato H
Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
[TBL] [Abstract][Full Text] [Related]
15. Administration of Intravenous Zoledronic Acid Every 3 Months vs. Annually in β-thalassemia Patients with Low Bone Mineral Density: a Retrospective Comparison of Efficacy.
Darvishi-Khezri H; Kosaryan M; Akbarzadeh R; Aliasgharian A; Fazli M
Med Arch; 2018 Jun; 72(3):170-173. PubMed ID: 30061760
[TBL] [Abstract][Full Text] [Related]
16. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
18. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
[TBL] [Abstract][Full Text] [Related]
19. Screening osteoporotic femoral neck without measuring bone mineral density with the use of tartrate resistant acid phosphatase-5b and serum-creatinine-to-cystatin C ratio in Japanese postmenopausal women.
Yoshii I; Chijiwa T; Sawada N
J Orthop Sci; 2020 Jul; 25(4):671-676. PubMed ID: 31337577
[TBL] [Abstract][Full Text] [Related]
20. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
